Table 2.
Description of the HIPEC treatment variables used by the participating groups.
| Variables | n |
|---|---|
| HIPEC TECHNIQUE | |
| Open | 18 |
| Closed | 11 |
| Closed-CO2 | 12 |
| HIPEC DRUG IN OVARIAN CANCER | |
| Cisplatin alone | 18 |
| Paclitaxel alone | 5 |
| Cisplatin + Doxorubicin | 2 |
| Cisplatin + Paclitaxel | 2 |
| Oxaliplatin | 1 |
| No HIPEC in Ovarian Cancer | 5 |
| TREATMENT REGIMEN (n = 28 groups) | |
| Cisplatin 100 mg/m2, 43°, 60 min | 3 |
| Cisplatin 100 mg/m2, 42.5°, 90 min | 2 |
| Cisplatin 100 mg/m2, 42°, 60 min | 3 |
| Cisplatin 75 mg/m2, 42°, 90 min | 3 |
| Cisplatin 75 mg/m2, 42°, 60 min | 3 |
| Cisplatin 80 mg/m2, 42°, 60 min | 2 |
| Cisplatin 50 mg/m2, 42°, 60 min | 2 |
| Paclitaxel 120 mg/m2, 41–42°, 60 min | 2 |
| Paclitaxel mg/m2 *, 41–42°, 60 min | 3 |
| Cisplatin 80 mg/m2 + Paclitaxel 120 mg/m2, 42.5°, 60–90 min | 2 |
| Cisplatin 80 mg/m2 + Doxorubicin 15 mg/m2, 42.5°, 60 min | 1 |
| Cisplatin 50 mg/m2 + Doxorubicin 15 mg/m2, 42°, 90 min | 1 |
| Oxaliplatin 200 mg/m2 + Doxorubicin 30 mg/m2 41.5–43°, 60 min | 1 |
* For every 2 L of solution for perfusion.